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 Abstract: 
Context: Animal studies suggest that cannabinoid receptor-1 (CB-1) blockade reduces 
inflammation and neovascularization by decreasing vascular endothelial growth factor 
(VEGF) levels associated with a reduction in inflammatory markers, thereby potentially 
reducing cardiovascular risk. 
Objective: To determine the impact of CB1 antagonism by rimonabant on VEGF and 
inflammatory markers in obese PCOS women.  
Design: Randomised, open-labelled parallel study. 
Setting:  Endocrinology outpatient clinic in a referral centre.   
Subjects: Twenty patients with PCOS and biochemical hyperandrogenaemia with a body 
mass index of ≥ 30kg/m2 were recruited. Patients were randomised to 1.5g daily of metformin 
or 20mg daily of rimonabant. 
Main Outcome Measures: Post hoc review to detect VEGF and pro-inflammatory cytokines 
TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 before and after 12 weeks treatment.  
Results:  After 12 weeks of rimonabant there was a significant increase in VEGF (99.2±17.6 
vs 116.2±15.8pg/ml, p<0.01) and IL-8 (7.4±11.0 vs 18.1±13.2pg/ml, p<0.05) but not after 
metformin (VEGF p=0.7; IL-8 p=0.9). There was no significant difference in the pro-
inflammatory cytokines TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 following 
either treatment. 
Conclusion: This study suggests that rimonabant CB-I blockade paradoxically raised VEGF 
and the cytokine IL-8 in obese women with PCOS that may have offset the potential benefit 
associated with weight loss. 
 
 
 Introduction: 
Vascular endothelial growth factor (VEGF) has a crucial role in inflammation and in vascular 
neogenesis, particularly in cancer [1, 2]. Animal studies have shown that cannabinoid 
receptor-1 (CB-1) blockade reduces inflammation and neovascularization by decreasing 
VEGF levels associated with a reduction in inflammatory markers [3]. Recent studies have 
shown that a reduction in VEGF levels may be associated with a better long term prognosis in 
cancer patients, with high VEGF levels being associated with a poorer prognosis [4, 5]. 
Weight loss induced by bariatric surgery has been shown to significantly reduce VEGF and 
other inflammatory cytokines, especially TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and 
MCP-1, potentially reducing cardiovascular risk [6-16]. In polycystic ovary syndrome 
(PCOS) patients, high serum and follicular fluid VEGF levels are associated with abnormal 
ovarian angiogenesis and dysfunction [17-20] and several studies have revealed improved 
ovarian function in these patients with decreasing VEGF levels [21-23]. Therefore, our 
hypothesis was that rimonabant, a CB-1 specific receptor antagonist, would reduce VEGF in 
PCOS by a decrease in weight and reduction in inflammatory cytokines and therefore such 
agents may be of potential benefit in the future. New human studies to look at this hypothesis 
could not be done as rimonabant was withdrawn due to side effects of depression and suicidal 
ideation and therefore a retrospective analysis of a previous study was undertaken [24]. 
 
Research design and methods: 
We performed a post hoc analysis of a study whose primary endpoint was to investigate the 
effects of rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients 
with PCOS. The secondary end-points were change in weight and waist circumference [24].  
It was a randomized open labelled parallel study with rimonabant 20mg daily or metformin 
(500mg three times daily) in 20 patients for 3 months: the study populations, designs, 
techniques and assays applied; along with informed written consent which have been 
described previously (Clinical trial registration ISRCTN75758249) [24]. All patients were 
women of Western European descent with a diagnosis of PCOS based on all three diagnostic 
criteria of the Rotterdam consensus, namely clinical and biochemical evidence of 
hyperandrogenaemia, oligomenorrhea or amenorrhoea and polycystic ovaries on transvaginal 
ultrasound [25] were recruited from Hull Royal Infirmary, UK. Study bloods and 
measurement were done after an overnight fast.  Compliance was monitored by counting 
returned medication.  
The Bio-Plex 200 system with HTF (Bio-Rad, Hercules, CA) was used to evaluate the sera 
and the levels of VEGF, TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-8, IL-10 and MCP-1 and 
compared to a set of standards that were run simultaneously in the assay.  
 
Statistical analysis and sample size calculation: 
The details of statistical methods used and power calculations have been explained previously 
in the original article [24]. The power of the study to demonstrate a significant reduction in 
total testosterone was based on a previous study showing a significant reduction in total 
testosterone concentration after treatment with metformin [26]. Using two-sided 5% 
significance level, a sample of 10 patients per group was found to be needed (assuming a 
20% dropout rate) to detect changes in total testosterone with 90% power. Comparisons 
between the metformin group and the rimonabant-treated group, with respect to percentage 
changes from baseline were carried out using the paired t test for biochemical data and 
clinical observations. The Wilcoxon signed rank test was applied to biochemical data that 
violated the assumptions of normality when tested using the Kolmogorov-Smirnov test. For 
all analysis, a two-tailed P ≤0.05 was considered to indicate statistical significance. Statistical 
analysis was performed using SPSS version 22.0 (SPSS Inc., Chicago, IL), and nQuery 
version 4 was used for sample size determination. 
 
Results: 
All 20 subjects recruited completed the 3-month study period.  The compliance was 98% in 
both groups by counting returned medication. The patients were weight matched in each 
group (Table 1). 
Weight reduced significantly after 12 weeks of rimonabant treatment (104.6 ± 4.6 vs. 98.4 ± 
4.7 kg, p<0.01) with a corresponding reduction in waist circumference (116.0 ± 3.3 vs. 109.2 
± 3.7 cm, p<0.01), hip circumference (128.5 ± 4.0 vs. 124.1 ± 4.2 cm, p <0.03) and waist hip 
ratio (0.90 ± 0.02 vs. 0.88 ± 0.01, p <0.01). In the metformin group these parameters were 
unchanged after treatment. There was a significant reduction from baseline in free androgen 
index (26.6 ± 6.1 vs. 16.6 ± 4.1 p<0.01) and testosterone (4.6 ± 0.4 vs. 3.1 ± 0.3 nmol/L 
p<0.01) but there was no significant reduction in the metformin treated group (free androgen 
index (FAI) p=0.38; testosterone p=0.57).  The percentage reduction in testosterone was 
significantly higher in patients treated with rimonabant for 12 weeks compared to the 
metformin group (-33.2 ± 5.0 vs. -7.5 ± 1.0 % p < 0.05).  There were no significant changes 
in sex hormone binding globulin (SHBG) in either group.  HOMA-β and insulin reduced with 
rimonabant (288 ± 150 vs. 268 ± 217, p< 0.05 and 20 ± 7 vs. 16 ± 6, p< 0.05, respectively) 
whilst metformin showed no effect (217 ± 104 vs. 217 ± 120 and 15 ± 9 vs. 15 ± 11, 
respectively). Both treatments reduced glucose levels that reflected in a significant reduction 
of insulin resistance from baseline for rimonabant (p<0.05), but not with metformin, albeit 
that, the absolute change in HOMA-IR did not differ between the 2 groups. There was no 
significant improvement in any of the lipid parameters or for hsCRP within or between study 
groups [24].   
There was a significant increase in VEGF (99.2±17.6 vs 116.2±15.8pg/ml, p<0.01) and IL-8 
(7.4±11.0 vs 18.1±13.2pg/ml, p<0.05) after 12 weeks of rimonabant treatment but not after 
metformin (VEGF p=0.7; IL-8 p=0.9). There were no significant changes seen in the pro-
inflammatory cytokines, TNF-α, IL-1β, IL-1ra, IL-2, IL6, IL-10 and MCP-1 following either 
treatment (Table 1). 
 
Discussion: 
This study showed that rimonabant increased VEGF and IL8 without affecting the other pro-
inflammatory markers in obese women with PCOS that might not be beneficial in this group, 
counteracting the potential benefits associated with weight loss. 
Angiogenesis is a vital aspect of normal ovarian cyclical function, essentially required for 
regular follicular development and growth. Studies have revealed that VEGF is the primary 
regulator of ovarian angiogenesis and VEGF pathway blockade is sufficient to disrupt 
ovarian angiogenesis and function [27]. PCOS is characterized by anomalous ovarian 
angiogenesis associated with increased ovarian expression and high follicular fluid 
concentration of VEGF, which is reflected in turn in their serum levels [28]. High levels of 
VEGF have been suggested to play an important role in PCOS pathophysiology and may 
contribute to ovarian dysfunction, subfertility and ovarian hyperstimulation syndrome 
(OHSS) [18, 29]. High VEGF levels have also been related directly to impaired insulin 
sensitivity in PCOS and reduced VEGF levels have been shown to cause significant 
improvement in glucose tolerance and insulin sensitivity in these patients and in diabetic and 
obese animal models, suggesting anti-VEGF therapy as a potentially novel treatment option 
in these patients [29-31]. Furthermore, significant reductions in VEGF levels have been seen 
in obese patients after weight loss, either by caloric restriction or by weight losing surgery, in 
addition to the significant improvements in metabolic parameters [32, 33]. However, in our 
study CB-1 blockade with rimonabant increased VEGF levels in PCOS patients even though 
they showed significant weight loss and improved insulin sensitivity after 12 weeks of 
therapy. This increase in VEGF is likely to be a pharmacological effect of rimonabant given 
that one of the suggested mechanisms for high VEGF levels in PCOS patients is 
hyperinsulinaemia [34, 35] that was reduced by treatment in this study.  
IL-8 levels were also significantly raised after rimonabant therapy that is a known 
proinflammatory and proangiogenic cytokine [36] and has been established as a risk factor 
for high cardiovascular risk [37, 38]. It has also been proposed to play a vital role in OHSS 
along with VEGF [39]. In vitro studies have shown that IL-8 enhances VEGF expression in 
endothelial cells by activating nuclear factor-kappa B (NF-kappa B) and stimulates hypoxia 
independent secretion of VEGF, which could aggravate ovarian dysfunction in PCOS patients 
by further stimulating abnormal ovarian angiogenesis [40]. Therefore, the increase in VEGF 
may be indirectly due to IL-8 stimulation.  
Studies have shown that cannabinoids are NF-kappa B inhibitors, so one of the other possible 
mechanisms of increased VEGF in our study could be direct activation of NF-kappa B by 
CB-1 blockade after 12 weeks of rimonabant treatment [41]. 
In summary, our study suggests that CB-1 blockade caused by rimonabant paradoxically 
raises VEGF and the pro-inflammatory cytokine IL-8 in obese women with PCOS that may 
have a direct deleterious effect and offset the potential benefit associated with weight loss. 
 
 
 
 
 Table 1: Comparison of cytokine profile before and after 12 weeks treatment with rimonabant or metformin 
Rimonabant Group (n = 10) Metformin Group (n = 10) 
Cytokines Baseline (V1) 12 Weeks (V2) P value Baseline (V1) 12 Weeks (V2) P value 
VEGF (pg/ml) 99.2±17.6 116.2±15.8 0.01* 110.3±25.2 111.5±24.8 0.7 
IL-8 (pg/ml) 7.4±11.0 18.1±13.2 0.04* 12.3±13.2 11.2±13.8 0.9 
TNF-α (pg/ml) 8.7±3.9 8.7±3.7 1.0 7.1±2.9 7.9±4.3 0.3 
IL-1β (pg/ml) 85.1±76.7 91.5±91.1 0.3 86.2±55.7 105.2±88.8 0.2 
IL-1RA (pg/ml) 576.9±126.5 609.7±118.5 0.4 592.5±211.3 683.7±418.2 0.3 
IL-2 (pg/ml) 17.8±8.5 21.9±13.3 0.2 23.0±17.1 35.4±57.2 0.4 
IL-6 (pg/ml) 16.8±8.4 18.5±9.5 0.3 12.2±5.9 13.2±7.3 0.3 
IL-10 (pg/ml) 10.2±6.3 10.1±5.8 0.9 23.0±32.3 27.2±29.9 0.3 
MCP-1 (pg/ml) 279.1±59.8 307.1±57.7 0.07 294.2±65.9 297.7±88.2 0.8 
 
VEGF= Vascular Endothelial Growth Factor, TNF-α = Tumour Necrosis Factor Alpha, IL-1β = Interleukin-1Beta, IL-1RA = Interleukin-1 receptor 
antagonist, IL-2 = Interleukin-2, IL-6= Interleukin-6, IL-8 = Interleukin-8, IL-10= Interleukin-10, MCP-1= Monocyte Chemotactic Protein-1 
Data are presented as mean ± SEM. *: Significant difference from baseline.  
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